QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.052258v1 306/3/1191    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kjølbye, A. L. Articles by Petersen, J. S. Search for Related Content PubMed PubMed Citation Articles by Kjølbye, A. L. Articles by Petersen, J. S.

CARDIOVASCULAR

Pharmacological Characterization of the New Stable Antiarrhythmic Peptide Analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH₂ (ZP123): In Vivo and in Vitro Studies

Departments of Pharmacology (A.L.K., J.S.P.) and Chemistry (C.B.K., T.J., B.D.L.), Zealand Pharma A/S, Smedeland, Denmark

Antiarrhythmic peptides (AAPs) are a group of compounds with antiarrhythmic properties; however, their use has been hampered by very low plasma stability. The aim of this study was to compare the in vitro and in vivo stability of our new stable AAP analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH₂ (ZP123) with the previously described AAP analog AAP10. Moreover, the effect of the two compounds was examined in a murine in vivo model of ouabain-induced second degree AV-block, and the effect on dispersion of action potential duration (APD dispersion) was studied during hypokalemic-ischemia in isolated perfused rabbit hearts. The in vitro t_1/2 of ZP123 in rat and human plasma was about 1,700 times longer than t_1/2 of AAP10. Due to rapid elimination, it was not possible to obtain an in vivo pharmacokinetic characterization of AAP10; however, calculations suggested that the clearance of ZP123 was at least 140 times slower than for AAP10. AAP10 and ZP123 produced a dose-dependent delay in onset of ouabain-induced AV-block in mice at doses of 10^-11 to 10^-7 mol/kg i.v. ZP123 and 10^-11 to 10^-6 mol/kg i.v. AAP10. Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10^-8 mol/kg i.v.) than with AAP10. In the isolated rabbit hearts, ZP123 and AAP10 had no effect on dispersion during control conditions. The increased APD dispersion during hypokalemic ischemia is considered a major arrhythmic substrate and only ZP123 prevented the increase in APD dispersion. In conclusion, ZP123 is a new potent AAP analog with improved stability.

Address correspondence to: Dr. Anne Louise KjØlbye, Zealand Pharma A/S, Smedeland 26B, DK-2600 Denmark. E-mail: alk{at}zp.dk

This article has been cited by other articles:

				A. L. Wit and H. S. Duffy Drug development for treatment of cardiac arrhythmias: targeting the gap junctions Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H16 - H18. [Full Text] [PDF]

				A. L. Kjolbye, M. Dikshteyn, B. C. Eloff, I. Deschenes, and D. S. Rosenbaum Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H41 - H49. [Abstract] [Full Text] [PDF]

				J.-q. Zhong, G. Laurent, P. P.-S. So, Xudong Hu, J. K. Hennan, and P. Dorian Effects of Rotigaptide, a Gap Junction Modifier, on Defibrillation Energy and Resuscitation From Cardiac Arrest in Rabbits Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 69 - 77. [Abstract] [PDF]

				A. Shiroshita-Takeshita, M. Sakabe, K. Haugan, J. K. Hennan, and S. Nattel Model-Dependent Effects of the Gap Junction Conduction-Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs Circulation, January 23, 2007; 115(3): 310 - 318. [Abstract] [Full Text] [PDF]

				J. M. Guerra, T. H. Everett IV, K. W. Lee, E. Wilson, and J. E. Olgin Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation Circulation, July 11, 2006; 114(2): 110 - 118. [Abstract] [Full Text] [PDF]

				J. K. Hennan, R. E. Swillo, G. A. Morgan, J. C. Keith Jr., R. G. Schaub, R. P. Smith, H. S. Feldman, K. Haugan, J. Kantrowitz, P. J. Wang, et al. Rotigaptide (ZP123) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 236 - 243. [Abstract] [Full Text] [PDF]

				J. Li, V. V. Patel, and G. L. Radice Dysregulation of cell adhesion proteins and cardiac arrhythmogenesis. Clin. Med. Res., March 1, 2006; 4(1): 42 - 52. [Abstract] [Full Text] [PDF]

				N. R. Jorgensen, S. C. Teilmann, Z. Henriksen, E. Meier, S. S. Hansen, J.-E. B. Jensen, O. H. Sorensen, and J. S. Petersen The Antiarrhythmic Peptide Analog Rotigaptide (ZP123) Stimulates Gap Junction Intercellular Communication in Human Osteoblasts and Prevents Decrease in Femoral Trabecular Bone Strength in Ovariectomized Rats Endocrinology, November 1, 2005; 146(11): 4745 - 4754. [Abstract] [Full Text] [PDF]

				D. Xing, A. L. Kjolbye, J. S. Petersen, and J. B. Martins Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H511 - H516. [Abstract] [Full Text] [PDF]

				S. Dhein Pharmacology of gap junctions in the cardiovascular system Cardiovasc Res, May 1, 2004; 62(2): 287 - 298. [Abstract] [Full Text] [PDF]